Pilot completes successful Airozin clinical trials
US specialty pharmaceutical company Pilot Therapeutics has completed a critical clinical trial that demonstrates that its lead over-the-counter (otc) medical food product, Airozin, safely reduces leukotriene levels in asthmatics. Airozin is the first otc medical food product for asthma and is intended to be added as a dietary component of a patient's existing asthma treatment programme. It is an oral, once-a-day medical food that inhibits the production of leukotrienes.
Leukotrienes cause many of the signs and symptoms of asthma and blocking their production is known to decrease the frequency and severity of asthma attacks. Approximately 20m Americans are afflicted by asthma, and this incidence is projected to double by 2020.
'We are very excited with the results of this trial,' said Dr Chilton, Pilot's founder, president and ceo. 'Our previous trials consistently showed that Airozin significantly blocks leukotriene production in non-asthmatic humans. This recent trial demonstrates that Airozin significantly reduces leukotriene levels in asthmatics.
'We know that asthmatics produce higher levels of leukotrienes than non-asthmatics, so this was a critical trial to prove efficacy. Based on the positive results of our five clinical trials, the company is preparing to launch Airozin into the marketplace.'